Trials / Completed
CompletedNCT00091663
A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Multicenter, Open-Label, Phase IIIb Trial of Tarceva (Erlotinib Hydrochloride) in Patients With Advanced Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 5,000 (planned)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase IIIb, multicenter, open-label trial of daily oral Tarceva in patients with advanced (inoperable Stage IIIb or IV) NSCLC who have progressed following standard chemotherapy treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tarceva (erlotinib HCl) |
Timeline
- Start date
- 2004-08-01
- Completion
- 2005-08-01
- First posted
- 2004-09-16
- Last updated
- 2014-03-04
Locations
92 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00091663. Inclusion in this directory is not an endorsement.